​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​

Modernization
Workgroups
Memorandums
Payers
Legal and Legislative
Acct and Budget Manual
Data Request
Patient Complaint Information
Trustee Disclosure Information
ED Wait Time Reduction Commission

HSCRC Overview

Welcome to the HSCRC
The Maryland Health Services Cost Review Commission (HSCRC) is an independent state agency ensuring all Marylanders have access to high-value, affordable healthcare. We regulate hospital rates, advance health system transformation, and support the innovative AHEAD Model to improve care quality, health outcomes, and cost-efficiency.​​​​  Lear​n More about the AHEAD Model.​

HSCRC June 2026 Commission Meeting – June 10, 2026

4160 Patterson Avenue, Baltimore MD 21215

 

The Commission will begin in public session at 12:00pm in the large public conference room

 for the purpose of, upon motion and approval, adjourning into closed session.

The open session will resume at 1:00pm

Topic: HSCRC June Commission Meeting – June 10, 2026

Time: June 10, 2026 1:00 PM Eastern Time (US and Canada)

Zoom Link to join webinar

Meeting ID: 410 764 2605

Passcode: 9Hm89B


 
Notices
Notice is hereby given that the public and interested parties are invited to submit written comments to the Commission on the following topic:  Request for Public Comment: HSCRC Regulations Evaluation, as presented at the May 13, 2026 Commission meeting. WRITTEN COMMENTS SHALL BE SUBMITTED TO [email protected] ON OR BEFORE June 12, 2026.
  • The public may comment on HSCRC’s current regulations, COMAR 10.37.01.00 - 10.37.12.9999 by June 12, 2026. HSCRC will gather submitted comments for the draft evaluation report. 
  • After submission on October 1, 2026, HSCRC will publish a notice in the Maryland Register that the evaluation report is available for public inspection and comment for 60 days.

Stay Connected
Have questions or suggestions? We’re here to help. Contact Us​

Cell and Gene Therapy Access Model
Mar​yland Medicaid is participating in CMS' Cell and Gene Therapy Access Model. Learn more.​